0:00Hey, guys. Welcome to the podcast. I have a very special guest, a repeat guest, a guy that I go to anytime I need some type of conversation that has anything to do with, like, digital or social or omnichannel. Guys, say hello to returning guest, Jason Howard. Jason, welcome back to the show, buddy. Excellent. Great to be here. Thank you for having me. Yeah. Why don't you do a quick intro for those that may not have listened to our prior episodes, which you should if you haven't.
0:31You gotta go back and find those. So why don't you do a quick intro? Absolutely. Thank you very much. So I'm currently with Boehringer Ingelheim, and I'm the global integrated medical communications pillar lead. So we're focused on pubs. We're focused on med info. We're focused on med ed, and then how that sits within a larger omnichannel umbrella. So, yeah, really excited to be breaking new ground and really excited to be here. So thank you. Awesome. Awesome. Well, thanks for coming back on. So, guys, ran into Jason at a conference, started talking.
1:04I'm like, dude, we gotta do something, man. Like, we just it's been too long. Let's do something. So came up with the idea of talking about the impact and journey of omnichannel. A lot of buzz still about omnichannel and medical affairs. Where are we at? What do we know? What do we need to change? How's it working? So we're gonna cover all that. Before we do, wanna mention very special sponsor for today, our friends at Medical Watch.
1:34If you guys haven't tried it, you really need to check these guys out. Medical Watch helps you understand what HCPs are saying about your products and diseases on social media. So everybody's talking about social listening, social monitoring. You can do this with Medical Watch, and it's free to sign up. So you go to medical.watch and sign up. You're gonna love it. I could tell you right now. People keep coming back to me like, oh, Tom. I thank you so much. I use Medical Watch. It's amazing. We are going to talk though right now about this omnichannel journey and where we're at.
2:11So, for for those that may not be aware, can you just give us a quick overview of what exactly omnichannel is when we hear that term? Yeah. Absolutely. So the easy, short, bite sized answer is right content, right channel, right audience, right time. Right? But there's a lot to unpack in there. It's an it's a short statement that means a lot. And the impact really, though, is personalized engagement. Can we provide an n of one experience for our HCPs?
2:42Can we anticipate their needs and then provide a positive customer experience? These are things that are traditionally thought of and discussed on the commercial side of the business, and we really do need to collaborate with them compliantly as we can, to think about that way as well. Because when you start looking at all the different touch points that medical has and those touch points are expanding with our HCPs, we wanna make sure that we're coordinated not with not just within medical, but also within the broader scope of your company, and then
3:12making sure that they're having a good customer experience in getting that information. I mean we think about customers from a product standpoint but from a medical standpoint we should also think about their experience in in getting education and information and moving the medical needle with us as well. Yeah. You know what? It's funny. I I so I've I've had we've I've had other conversations with folks even on this podcast and just at conferences about omnichannel, and I've been to a lot of discussions. And I'll be honest with you.
3:43Like, the first couple times I heard it, I just still didn't understand it. And then someone someone got up and talked about and they said, okay. Let me explain it this way. Mhmm. You go to restaurant. Let's say it's your favorite restaurant or let's say it's a restaurant you frequent. Okay. You walk in, everyone knows your name. They know what your favorite table is. They know what your favorite specials are. They bring you your drink when you literally, without you even asking it.
4:15They know the bottle of wine that you want, and then they bring the dessert selections out, but they comp the your favorite dessert because they know or they know it's your birthday. So it's personalized to the individual based upon their preferences. Is that a good way to describe it? That's perfect. And, actually, that's a great analogy for what MSLs have always been doing. Right? Think about that. MSLs know what to talk about with what HCP at what time. Oh, I I avoid this topic with this person.
4:47It's sort of a hot button issue. Mhmm. Oh, I really know that they're interested in safety. I really know this person's interested in overall survival. You know you as an MSL we've always been doing that and when I talk to field teams about what does medical omnichannel look like for them, my answer to them is you've been doing it from the beginning. You've been providing that personalized engagement and that's why you know, you've built these really valuable relationships with HCPs from a company standpoint. We need to get our house in order. We need to be able to say that the digital channels are integrated, that the emails are
5:21integrated, the content is integrated. So, basically, when the MSL makes that choice to pull that lever at that time, they are put in a position to be optimally engaged. Right? So this is really more of a headquarters transformation than it is for the MSLs. To your point, they are the ones that have already been running the restaurant. They know the HCPs. They're doing it fantastically. We need to help them do it better. Yeah. Awesome. So this concept isn't new.
5:51So omnichannel is not a new term. It's not a new concept. But as it relates to medical affairs, is is it widely adopted? Are we still scratching the surface? Like, where do you think we are in in this journey as it relates to medical affairs? For medical I think we're somewhere in the middle. We've been having this conversation within medical affairs for a while now, at least four or five years. So we're definitely not scratching the surface. I would say that no one person in the space has also unlocked the entirety of omnichannel on
6:29the medical side. Right? So I would say that different companies are in different states of maturity on different aspects of omnichannel. Are there some that are really advanced in their content creation and content approval processes? Yes. Are there some that have just fantastic websites that are replete with a lot of different information and very engaging and then also allow them to be able to measure that and take that next step? I would say yes. Right? Are are there really engaging MSL email campaigns that are being created and being able
7:01to measure for impact and customer engagement and all these types of things, open rates. Yes. So does everyone have all the pieces in place yet? I would say no. But different groups are in different states of maturity on these different aspects of omnichannel, which is exciting to see. And who needs it? Like, what types of companies should have adopted or be adopting omnichannel? The easiest answer is someone who needs to do more with less.
7:32Right? So what does that look like? Let's say you have a very large or very diverse audience. Oftentimes, these are products that are being utilized almost exclusively by primary care physicians. Right? In The United States, that could be, what, 5,010, eight you know, PCPs as opposed to, let's say, you're looking at a rare disease. Right? There's a very, very big difference in your content needs and your engagement needs. So I would say the companies that need to be most focused on omnichannel are the ones with
8:02large diverse audiences where you're gonna need to be tailoring content creation so one size doesn't fit all. More with less. Can you increase the reach of your field team then by augmenting them with digital channels, with digital outreach? Right? Because, honestly, let's let's be honest. MSLs, it's a spend. Right? It's expensive to have a field team. So you want them to be focused where their value is the greatest, but also you can't overwhelm them either and say, alright. Here's your US, PCP list.
8:34It's a thousand people. Go to it. Right? You can't you can't do that either. So you're gonna have to find that balance of where they need to be engaged and with whom and how do you augment that then with digital resources around them. So those are sort of the portfolios and companies that should be most focused on maximizing their engagement with omnichannel. And then so who shouldn't? Like, there's gotta be some words of caution to certain companies that may not want to adopt an omnichannel strategy. Is that correct? Absolutely.
9:04You know, let's say you're a biotech that's focused on one rare disease. Right? Your audience is probably pretty small and highly specialized. So in that sense, you know, a multichannel approach could be fine because one one approach one, you know, fits all. So who doesn't need it? Your audience is small, highly specialized. You know, we had sort of a joke within the rare disease space, that they don't have KOLs. They have STPs. And the joke was that it's the same 10 people.
9:36Right? So that doesn't mean that they're not important. They're very important. That's why they're the same 10 people. But you don't need to take a, you know, a four persona approach to maybe 15 KOLs. Right? So it's it's it's it's a lift. It can be expensive to do omnichannel. So you should be deploying it where it makes sense. Yeah. So that's a great term. STP, same 10 people. Like, that that's a new one. I never heard that before. So, you know, sometimes people ask me like, well, what did you learn?
10:07What'd you learn from the the episode this week? That's gonna be one of the things I would say is, yeah, I learned Same 10 people. And they're important people. Yeah. You really need to make sure. But odds are you've been personalizing for them from the beginning. Right? You're not gonna be taking a company wide approach to start segmenting, you know, fifteen, twenty people. It's important. It's really important. But, you know and also if you have a key market that doesn't allow integration of your channels, that can be a place where you can't do omnichannel.
10:37And maybe your messaging needs to be more uniform and more regulatory. Hey. Here's a really fast regulatory update we need to provide. You're not creating persona driven versions of that. You're creating it. You're getting it out as quickly as possible, and that's meeting your need. That's meeting your customers where they are. So those are those are key examples where, you know, omnichannel is probably overkill. Yep. And then I obviously, I have the expert here, so I I have to ask you. How does like, what like, how important is it to incorporate digital and social channels into
11:11the omnichannel strategy? There are critical ways to expand the impact of your team. So I sort of hinted at it earlier, but let's take a deeper dive on that part. I think we all know that the value of your field team, your infield team, is prelaunch, postlaunch, that whatever you want to call that that peri launch phase. Mhmm. Some companies say it's three years pre launch some people say five whatever that is. That's where they need to be. But when you look at your medical portfolio right it goes back.
11:41It can go back to phase one, you know, and particularly we have a lot of KOLs that wanna have those pipeline conversations where they're going, I I wanna know what's coming in five or ten years. I already know what's here today. Right? Or hey. The KOL is not really interested in talking about something that's near loss of exclusivity. So why is your field team involved there? That doesn't mean you can't provide and shouldn't provide medical support. So you can take a look at your channels, email, websites, apps, you name it, chatbots, social,
12:13and say, okay. What's our channel mix across our portfolio? Does it make sense to have 30 or 40% field deployment on an asset that's near loss of exclusivity, or should it be 90% pull content from our websites? Then you can demonstrate to your leadership, hey. We're not not providing medical support. We're doing it in the most effective and cost effective way possible by augmenting the field team and focusing them and saying, here's where you're gonna be focused for your value, but then expanding out the reach from a digital perspective and being able to capture that.
12:46So you can get anything from phase one to LOE. We're using omnichannel strategies. Wow. Awesome. So let's talk about social media. Can you give some examples of how companies should be using social media these days? We've asked a lot of HCPs in the past what they're looking for from from pharma, right, particularly in the social spheres. And the answer that comes up time and time and time again is infographics. They say to us, look. You've got this publishing capability.
13:18You have this budget to create really engaging infographics that take these complicated situations and really boil them down to something that's a snapshot. That's one picture. You know, a picture says a thousand words. Great. Well, then what do you do with it? How do you how do you disseminate it? How do you get it to resonate with and they said, look. A lot of people said in the social spheres, that's what we're looking for pharma to engage with. Give us that content that we can engage peer to peer. Hey. What do you think about this? Does this resonate?
13:49Is this practice changing? Right? Have that thing that they can engage on. And then if it's disease state, they can share with their patients. Right? So they're asking for these tools to be able to be used with their colleagues, with their patients. That's that's the number one way. The other one is closed HCP networks. Right? So you can create closed HCP networks, for example, on LinkedIn. It sort of helps from the content standpoint that it's not generally available, and you can control who's in there.
14:19And then it's sort of like a standing ad board. Right? And then the other way you can do it is contracted DOL engagement. So contract with a digital opinion leader, co create content with them, and then they can have that discussion with their network. So there's lots of really fun and interesting ways that you can start engaging on social from a medical perspective that are completely compliant. Now you gave great examples. Are companies I kinda almost feel like this is still a gap. Are companies doing a good job with this, or is this one of those areas where they're like,
14:52we're not there yet. We really need to do more. Yeah. I I think this is a really splintered economy, the one you're talking about there, because it ties back to every company has a different, appetite for risk. Right? Different companies see this engagement strategy as a certain level of risk. And if that company is comfortable with that, then, you know, those stakeholders can make a lot of progress there. If they're not, then you're not gonna see the light of day and it's not gonna move forward. So we have I have seen in my experience there tends to be more leeway around US targeted
15:30content. Right? So so if you are let's say a 100% focused on The US or disproportionately focused on The US, then that's an opportunity there. Different companies are evaluating what's called dark posting, meaning basically targeted placement of information within an HCP's feed. Right? And you can do that in The United States. Some companies feel like, alright. Well, if you're spending to get that engagement, then that's really a commercial
16:01activity. Others say, well, you're if you're allowed to have a proactive email engagement, what's the difference between having a proactive US, social engagement that you have guaranteed isn't going out globally because you've you've paid to post it within specific US stakeholders that you've predefined on a, you know, on a on a proactive engagement strategy. So it really depends on which company you're in. Yeah. Yeah. Because I hear about this. And and and I think there's a competitive advantage for the ones that are out ahead of
16:33it. Yeah. Yeah. I totally agree. And you're you're seeing, HCPs the the the percentage of HCPs that are digitally engaged is growing Yeah. As millennials and Gen z age into the majority of the HCP population. Right? So they've been digitally engaged from the beginning. They're used to it. That's where they go. Right? So, you know, I I learned a great lesson from my corpcom colleagues and that was go where
17:04your audience is. Yeah. And so if they're not on social, then it's not for you. But if they are, then you're missing an opportunity. Yeah. It's funny. One of the first episodes that I did ever on social media is couple years ago now. It might be two or three years ago. It's another Jason. Jason DeMuth said, you have to meet them where they live. That's right. And that takeaway, I was like, okay. So if everybody now KOLs, if they've adopted a certain social outlet let's just say it's
17:37Twitter. Let's say it's or x. You know? Let's say it's YouTube. Let's just say that there's a KOL that has this amazing YouTube channel and obviously has adopted that social medium. Well, then they're saying it's okay. They're saying, I'm this is where I am and this is where I wanna be, and I expect to have an audience. So if you choose not to be a part of their audience, I think you're missing out. Am I overstating that? No. You're not overstating that at all.
18:08I think that's that's absolutely it. And you also touched on another thing which is these different disease states actually have preferences for different platforms. So you have to go through this. Let's look at my portfolio and say where are they? Right? As someone who was disproportionately focused on oncology, I was laser focused on x. Yeah. Because where a lot of oncology debate was. Okay fine. But you know in a portfolio where you have a lot of dermatology indications, you need to be
18:38on Instagram because that's where they are right? You're dealing with visual diseases on a visual medium they're over on Instagram. Let's say your patient pop let's say your HCP population is really more primary care then you need to be over on Doximity and Surmo. They're disproportionately not arguing on x. Those are your KOLs. So you really have to kind of like look on a case by case basis what is your HCP population, what is your disease state, and then where are they? And you'd be surprised at how splintered it can get.
19:10So you really have to kinda do it on a case by case basis. So this really is it's here. Like, we really need to pay attention to this piece of the equation or we're missing a critical piece. Absolutely. And you mentioned we you you and I were having a conversation, and you mentioned that certain therapeutic areas and disease states dominate certain social channel, like you just said, or are more prevalent. So can you talk about, like, the hierarchy of and and how prevalent I think you mentioned
19:45oncology. Am I right? Is So if you're in luck, if you're covering oncology or cardiovascular. Okay. Those are the two most engaged subspecialties of medicine online. It's not even close. There and I've asked sort of, you know, I've I've met with these people over the years and this is an interest of mine. You know, I just kinda wanted to know why and I really haven't gotten a clear answer. You know, they have a lot of theories. Right?
20:15Oncology has a lot of new data releases. It's hard to keep up with the news. There's a lot of new regulatory approvals. You know, the data moves really fast. We need to discuss it in real time. Is that why so many oncologists are on x? You know, another interesting theory that I've had that's been put to me was, well we have a lot of competing treatments in these different, disease states within oncology and a lot of them have sort of the similar outcomes if you just look at overall survival.
20:47So having that debate of yes it's this versus yes it's this is really warranted whereas let's say you had a rare disease where it's the only drug in the space, it's a 100% effective, it's doing you know phenomenal. There's really no debate about within space unless there's another competitor there's really no debate that's your answer for this patient population. Great. So it's interesting to see what the options are within given indications may be driving the level of conversation, but, you know, that's just a hypothesis.
21:21Okay. So, obviously, this is very important, and we see everybody's you know, companies are paying attention to this. And so how should companies be using social monitoring and social listening in their omnichannel strategy? So omnichannel one of the big pillars of omnichannel is data and analytics. Right? And one of the biggest analytical signals that I'm a fan of is medical insights.
21:52Right? So what are people talking about? We traditionally do that through MSL meetings with HCPs. They put it into the CRM. That's a source. You have a public source with social media monitoring. It it's it's right there. It's a great opportunity, like I said, particularly if you're in oncology, particularly, if you're in cardiovascular. So if you are not looking at these types of insights, if you're not looking at this public debate, then you have a blind spot. You have a blind spot in your analytics that could be helping make a more mature omnichannel
22:26future. Right? So if you the the value of your omnichannel is directly proportional to the amount of information you're taking in. Right? Can I have what's called next best action for an HCP if I don't have an understanding of where they're going, what they're talking about, what they're interested in? And if they're a DOL, you know, that's a huge opportunity to be able to drive that personalization. They're putting it right out there. And in fact, in my experience, when I've met with DOLs in the field, they are the most
22:59engaging. And I shouldn't be so surprised because they're already doing it on a digital platform. They're also like that in real life. And so they're almost putting themselves out there saying, I want to be engaged with. So that's helpful from an engagement perspective as well. Well I think that we're that's where we're at right now. I think that MSLs need to be almost like digital first in the way they do their research, gain an understanding of their KOLs, their k o KOL list, where those KOLs live, what
23:31social channels they've adopted Yep. What their personalities, what their stance is, what's important to them, what's hot to them. I mean, I just think that there's there's this is low hanging fruit in in a lot of in certain situations. But when it's not that easy to like, are there social listening and social monitoring tools that you recommend? Yeah. Yeah. Absolutely. And, you know, I like to sort of talk about the spectrum of options. Right? Because, you know, some of us are working for biotechs that are just starting.
24:03Yeah. And they may not have the budget. And some people are in top 10 pharma, and they have a lot of options available to them. So Yeah. You know, look. If you're looking to just start scratching and get started and just dive in, you know, Sprinklr is cost effective. You do have to pay some. You mentioned MarketWatch at the top of Medical Watch is free. You mentioned Medical Watch. I've signed up. I get, you know, sort of an email download my directly to my inbox.
24:36It's free. It covers oncology, which I'm interested in. Yeah. And, yeah, it was it's so I can rank, you know, my my KOLs and and by impact. I can look at the different you know, I can select different not only disease states but also products that I'm interested in. Yeah. So yeah. It's it Medical Watch is a really nice one as well. I would I would definitely recommend that. If you have some other budget, you know, I've I've had good experience with Brandwatch. I've had great experience with AccelerationPoint. I've had great experience with Synthesio as well.
25:08Those are I I would put them sort of in the category of like Cadillac products. Right? You're gonna you're they're they're good, but you know, you're gonna have to have a significant budget to support it. So Yeah. Just know that when you're looking at your options. Yeah. But there are definitely great entry point options and there are then they are, you know sometimes people like to buy Alexis as well. Yeah. Well, and I think that the we're at a point where these, you know it's it's become a mandatory. I think everybody needs to to be out there paying attention and being diligent and making
25:41this a part of their strategy. And and, you know, and and I don't know if it falls under competitive intelligence or what I mean, I don't know exactly where it falls under, but you really need to be on top of this to have a competitive advantage. Yeah. You can find there's essentially free ad boards. Right? Particularly on you know, what we've seen is that HCPs don't like to debate science on LinkedIn. They like to sort of and and by the way, that platform's closed, so it's not really included
26:12in a lot of social media monitoring platforms anyway. But they like to use that for networking. Okay. Great. Then you should not be thinking about creating content necessarily to stimulate that type of scientific engagement for that platform. Awesome. But you gotta know that. Right? And you gotta take a look on a case by case basis. And when you have a new data release and you have a new FDA approval and it stimulates that back and forth with HCPs and KOLs online, it's a free ad board. You're sitting there taking it all in.
26:43I've I've had these conversations internally and some people have said well, you know, maybe they're putting something that's a little rosy out there because it's in public. Why should I why should I believe this? They're maybe putting a public spin on this information that that is, you know, maybe a little too rosy. And in my experience, I've this is the best peer review you could possibly have because all these HCPs are trying to demonstrate their value. Right? So if something is said on a scientific level that maybe they don't agree with, trust me they
27:18point it out. It starts that conversation. So you know we put a lot of value in peer review for publications and that's three or four people on one panel. You put something on x and you're putting your reputation on the line and thousands of people are reviewing that. And if there's no rebuttal, I would put a lot of stock in that conversation. Great point. That's a great point. So what do you where do you see things going? Obviously, we talked about the journey. We talked about some of the particulars. But where are we going with this?
27:50What's next in omnichannel? So the big the big, I think, opportunity is to bring what's called next best action. Right? So you sort of talked about it in the rest let's take it back to that restaurant analogy. They had an analog version of that. Right? They knew they know your birthday. They know your cocktail. They know, you know, what they wanna bring you. So they have that next best action in mind. Can we do that from an automated standpoint and do that within the medical realm? The real trick here is, you know, commercial is built to be proactive.
28:24And depending on where you are in the world and what your disease state is and where you are, you have a lot of limitations on how proactive you can be from a from a medical perspective. So can we bring next best action? It may be called next best engagement. It may be called next best suggestion. Right? But can we automate what that next step for that n of one experience would be? So let's say you're an MSL. You're doing your pre engagement planning, you look in your CRM, and now you have alerts that
28:57say, based on the totality of information we have about this HCP you're about to meet, we think that they might be interested in this information, this information, or this information. Right? It's not a mandate. You're not saying you must go out and cover these topics. It's, hey. This is the Netflix or Amazon way of saying, we saw you look at these five things and based on what we know, you might like these five things too. Right? So Netflix already does this really well. Amazon really does this really well. Can we do this in a medical sphere?
29:29I think we have a lot of people looking at it, and and I'm interested in being participating in as well. It makes sense, man. I think this is the future. So as always, appreciate you coming on, brother. Did not disappoint. You're always, you're always ahead of the game when it comes to all this stuff. So thank you. Thank you for sharing your wisdom. Thank you for giving me the opportunity. Yeah, man. Alright, guys. Hope you got a lot out of this. If you did, please share it with others. Always appreciate your support, your comments. Don't forget to connect with me on LinkedIn if you haven't already, and give me your feedback.
30:00Love to hear from you guys. So, love you all. See you all next time.